CS
NVIV

Credit Suisse’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Credit Suisse’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1
Closed -$54K – 4229
2016
Q4 		$54K Hold
1
– – ﹤0.01% 4015
2016
Q3 		$86K Sell
1
-1
-50% -$125K ﹤0.01% 3950
2016
Q2 		$254K Buy
2
+1
+100% +$118K ﹤0.01% 3764
2016
Q1 		$86K Buy
+1
New +$107K ﹤0.01% 3846
2015
Q4 		– Sell
-1
Closed -$94K – 4461
2015
Q3 		$94K Hold
1
– – ﹤0.01% 4110
2015
Q2 		$394K Buy
+1
New +$264K ﹤0.01% 3872

Other funds holding NVIV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse's NVIV Position: Q1 2017 in Review

Credit Suisse sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2017, closing a stake of 1 share — an estimated $54K sold.

Credit Suisse first reported a position in NVIV in Q2 2015 and held it in 6 quarters. The position peaked at $394K in Q2 2015. 42 funds tracked by Wall St. Rank hold NVIV as of Q1 2017.

  • Credit Suisse reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2017 after selling out during the quarter.
  • Credit Suisse sold 1 InVivo Therapeutics Holdings Corp share in Q1 2017, an estimated $54K.
  • Credit Suisse first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 6 quarters.
  • Credit Suisse's InVivo Therapeutics Holdings Corp position peaked at $394K in Q2 2015.
  • 42 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2017.

Based on Credit Suisse's 13F filing for Q1 2017, filed 15 May 2017.